Navigating the AI Frontier: A Deep Dive into CDSCO’s Software as a Medical Device Regulations

How India is regulating AI in healthcare and what MedTech innovators need to know about the latest guidelines.

The intersection of Artificial Intelligence (AI) and healthcare is no longer a futuristic concept; it is happening right now. From AI-powered radiology software detecting early signs of tumors to predictive algorithms managing chronic diseases, AI is revolutionizing patient care. But for developers and manufacturers, this rapid innovation brings a critical question: How do you regulate a medical device you cannot physically touch?

For a long time, the regulatory landscape for AI and software in India operated in a gray area. However, the Central Drugs Standard Control Organization (CDSCO) has stepped up to bring structure, predictability, and safety to this rapidly evolving sector.

Here is a complete breakdown of the CDSCO regulations governing AI and medical device software, and how you can seamlessly bring your digital health tools to the Indian market.

The Big Shift: CDSCO Guidance on Medical Device Software

In late 2025, the CDSCO issued a landmark Draft Guidance Document on Medical Device Software. This document clarified exactly how the existing Medical Devices Rules (MDR), 2017 apply to software across its lifecycle. The guidance was a massive relief for developers who previously struggled with “threshold uncertainty” — the confusion of not knowing if their software product legally qualified as a medical device.

The framework draws a crucial functional distinction between two categories:

• Software in a Medical Device (SiMD): This is software embedded within hardware that cannot perform a medical purpose on its own. For example, the firmware that controls an insulin pump or drives a cardiac pacemaker.
• Software as a Medical Device (SaMD): This is the category where most AI innovations land. SaMD is standalone software that independently performs a medical purpose without being embedded in physical hardware. Examples include AI-powered computer-aided detection software, clinical decision support systems, or mobile apps analyzing medical images.

How is AI Classified by the CDSCO?

Just like traditional physical devices, AI and SaMD are subject to a strict risk-based classification framework. The CDSCO categorizes software into four classes (Class A to D) based on two primary factors: the significance of the information the software provides and the seriousness of the healthcare situation it addresses.

• Class A (Low Risk): Basic software used in non-serious situations, like an application reminding patients to take their daily medication.
• Class B (Low to Moderate Risk): Software that supports clinical management, such as an AI tool tracking heart rates for unusual patterns.
• Class C (Moderate to High Risk): Software that plays a direct role in diagnosing or guiding treatment decisions in critical clinical scenarios, like an AI model detecting early signs of cancer from diagnostic reports.
• Class D (High Risk): Critical, life-supporting AI systems where a malfunction or incorrect data output could be fatal.

The Game Changer: The Algorithm Change Protocol (ACP)

One of the biggest hurdles in regulating AI globally is that machine learning models are inherently designed to learn, evolve, and change over time. If your AI model updates itself to improve diagnostic accuracy, do you need to pause operations and re-apply for CDSCO approval every single time?

To address this reality, the CDSCO introduced the Algorithm Change Protocol (ACP). This protocol requires developers to specify in advance how algorithmic updates or retraining will be managed, validated, and reported to regulators. It is a forward-thinking approach that acknowledges the evolving nature of AI, ensuring patient safety without stifling innovation through rigid compliance loops.

The Compliance Challenge: Do Not Go It Alone

While the CDSCO has provided much-needed clarity, getting an AI medical device registered remains a highly technical and rigorous process. Manufacturers must maintain exhaustive documentation, including software architecture files, algorithmic transparency data, clinical evaluation reports, and an ISO 13485-compliant Quality Management System (QMS).

A single misclassification or a gap in your clinical validation data can lead to immediate application rejection, derailing your product launch timeline and burning through vital capital.

Accelerate Your MedTech Innovation with Operon Strategist

This is where having an expert regulatory partner becomes invaluable. If you are developing an AI-driven medical device or SaMD, navigating the CDSCO’s evolving digital health guidelines requires specialized, up-to-date knowledge.

**Operon Strategist** simplifies this complex regulatory journey. As a leading global medical device consulting firm, they offer comprehensive end-to-end support for software medical devices. From accurate risk classification and compiling your technical documentation to managing clinical evidence packages and handling CDSCO portal submissions smoothly, Operon Strategist ensures your AI innovation gets to market quickly and compliantly.

Do not let regulatory hurdles slow down your groundbreaking technology.

👉 **Discover how Operon Strategist can streamline your CDSCO Registration today.**